MedTrace Logo

Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations

NCT02648958 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2018-06-13

No results posted yet for this study

Summary

Ischemia reperfusion injury causes the release of free oxygen radicals. The selective alpha2-receptor agonist, dexmedetomidine, has an inhibitory effect on inflammatory responses during ischemic injury. The aim of this study is to evaluate the effect of dexmedetomidine on inflammatory responses during ischemia-reperfusion injury in skeletal muscle.

Conditions

  • Arthroplasty, Replacement

Interventions

DRUG

Dexmedetomidine

The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.

DRUG

normal saline

The control group received the normal saline infusion

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • YONGSEON CHOI · Assistant professor

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648958 on ClinicalTrials.gov